77.50 -0.05 (-0.06%)
After hours: 7:47PM EDT
|Bid||77.29 x 1300|
|Ask||77.60 x 800|
|Day's Range||76.00 - 77.64|
|52 Week Range||65.25 - 92.64|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||19.66|
|Earnings Date||Jul. 31, 2020|
|Forward Dividend & Yield||2.44 (3.16%)|
|Ex-Dividend Date||Jun. 12, 2020|
|1y Target Est||93.94|
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
U.S. stocks closed higher on Tuesday on optimism about the development of coronavirus vaccines and a revival of business activity, but the S&P 500 failed to hold above the key psychological level of 3,000 points. Stocks pared gains late in the session, after Bloomberg News reported the Trump administration was weighing a range of sanctions on Chinese officials, businesses and financial institutions, reinforcing comments earlier in the day from White House adviser Larry Kudlow.
Stocks jumped Tuesday, and the S&P 500 traded above 3,000 for the first time since March 5, as hopes for an effective coronavirus vaccine combined with optimism over updates around states’ reopenings. Each of the S&P 500 and Dow traded above 2% shortly after market open.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Merck & Co Inc , which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. Merck did not disclose the terms of the acquisition of Themis, a privately held company.
Merck & Co Inc, which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately-held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. It did not disclose the terms of acquisition of Themis, a privately held company.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition — both areas of high unmet need.
LYNPARZA Approved by FDA for Treatment of HRR Gene-Mutated mCRPC That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
With increasing life expectancies and aging global populations comes higher prevalence of neurodegenerative disease. Merck is betting big on being the pharma company of the future.
Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.
Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.
Wells Fargo Asset Management Multi-Asset Strategist Brian Jacobsen joins Yahoo Finance’s Seana Smith to discuss the market rally amid optimism over Moderna's coronavirus vaccine data.
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Trump revealed the newest plans to develop vaccine, but later said the country will make a comeback with or without it. Board Certified Specialist in Preventive Medicine & Public Health Dr. David Katz joins Yahoo Finance’s Seana Smith to discuss.